

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/575,051	04/03/2006	Giancarlo Tonon	02901/0203976-US0	5959
7278 DARBY & DA	7590 08/14/200 ARBY P.C	EXAMINER		
P.O. BOX 770)	LONG, SCOTT		
Church Street New York, NY			ART UNIT	PAPER NUMBER
			1633	
			MAIL DATE	DELIVERY MODE
			08/14/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/575,051	TONON ET AL.		
Examiner	Art Unit		
SCOTT LONG	1633		

	SCOTT LONG	1633					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress				
THE REPLY FILED 23 July 2008 FAILS TO PLACE THIS APPL	ICATION IN CONDITION FOR AL	LOWANCE.					
 X The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance, (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	the same day as filing a Notice of a eplies: (1) an amendment, affidavi al (with appeal fee) in compliance FR 1.114. The reply must be filed	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
 a) The period for reply expires 3 months from the mailing date 							
no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TW MONTHS OF THE FINAL REJECTION. See MPEP 768 07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as				
The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with the	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
AMENDMENTS							
The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE below the control of the control	sideration and/or search (see NOT v);	E below);					
 (c) They are not deemed to place the application in beti appeal; and/or 	er form for appeal by materially rec	lucing or simplifying t	ne issues for				
(d) ☐ They present additional claims without canceling a c	orresponding number of finally reje	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (l	PTOL-324).				
Applicant's reply has overcome the following rejection(s):							
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 	owable if submitted in a separate, t	imely filed amendmer	nt canceling the				
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of				
Claim(s) allowed: Claim(s) objected to:							
Claim(s) rejected:							
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE							
The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
The affidavit or other evidence filed after the date of filing- entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a				
 The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 	of the status of the claims after er	ntry is below or attach	ed.				
The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:				
 12. Note the attached Information Disclosure Statement(s). 13. Other: 	PTO/SB/08) Paper No(s)						
	/Janet L. Epps-Ford/ Primary Examiner, Art U	nit 1633					

Continuation of 11. does NOT place the application in condition for allowance because: The applicant has not submitted any claim amendments. Rather, the applicant has submitted arguments in response to the new grounds of rejection based upon claim amendments (filed 1/29/2008).

Basically, the applicant argues that the teachings of Schauer and Fontana do not teach the specific construct of the instant application used to knock out the CMAH gene. Specifically, the applicant argues that Fontana and Schauer do not teach knocking out specifi portions of the gene between exons 8 and 15 (i.e., bases 787-1598 of cDNA encoding for CMAH) (Remarks, page 6, parag.2). The applicant seems to put great importance in the deletion of bases 7878-1598 of CMAH cDNA, but the specification does not indicate that this region alone is capable of eliminating CMAH activity from CHO cells. Because Schauer and Fontana indicate that removing AHA activity from CHO cells is the goal of their invention and that targeting vectors may contain large portions of the CMAH genomic DNA, encompassing 5' or 3' non-coding sequences and introns and exons, it seems that bases 78-71-598 of the cDNA of CMAH would be comprised by their targeing vectors. Therefore, the examiner finds the applicant's arguments unpersussive.

In addition, the applicant suggests that Schauer and Fontana might not be enabled for their general teachings encompassing knockouts of CMAH gene in CHO calls (Remarks, pages 6-7), because "gene targeting by homologous recombination in mammalian somatic cells is difficult and unpredictable" (Remarks, page 6, pareg 4). The applicant suggests that the examiner has not articulated the reasons why a skilled artisan would have recognized that the results of the prior art were predictable. While gene targeting by homologous recombination in mammalian somatic cells may be difficult, it has become routine in many molecular biology laboratories around the world. In fact, this technique is performed so commonly, that between January 1, 2008 and August 6, 2008 there have been 45 patents issued that have the terms "homologous recombination," "gene targeting," and "cho cells" in their claims. So while the applicant may believe that this technique is difficult and unpredictable, the examiner believes the skilled artisans of these 45 patents would believe this technique to be difficult but predictable.

Accordingly, the instant claims 18-27 remain rejected for the reasons of record and the comments above.

/SDL/ Scott Long Patent Examiner, AU 1633